Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator
about
Correcting the cystic fibrosis disease mutant, A455E CFTRMechanisms of CFTR Folding at the Endoplasmic ReticulumH662 is the linchpin of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter HlyBBAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP.The ABC protein turned chloride channel whose failure causes cystic fibrosisCFTR gating II: Effects of nucleotide binding on the stability of open statesCystic fibrosis transmembrane conductance regulator dysfunction and its treatmentIntegrated analysis of residue coevolution and protein structure in ABC transportersStructures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutantABC ATPase signature helices in Rad50 link nucleotide state to Mre11 interface for DNA repair.Crystal structure of the maltose transporter in a pretranslocation intermediate stateRequirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCrystal structure of a heterodimeric ABC transporter in its inward-facing conformationDistinct roles for the Hsp40 and Hsp90 molecular chaperones during cystic fibrosis transmembrane conductance regulator degradation in yeast.Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesDiminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfoldingThe primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domainRescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementationNew insights into interactions between the nucleotide-binding domain of CFTR and keratin 8.Stabilization of Nucleotide Binding Domain Dimers Rescues ABCC6 Mutants Associated with Pseudoxanthoma Elasticum.Development of CFTR StructureATP and AMP mutually influence their interaction with the ATP-binding cassette (ABC) adenylate kinase cystic fibrosis transmembrane conductance regulator (CFTR) at separate binding sites.Charge environments around phosphorylation sites in proteins.Folding and rescue of a cystic fibrosis transmembrane conductance regulator trafficking mutant identified using human-murine chimeric proteinsNormal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain.The cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in maturation stage ameloblasts, odontoblasts and bone cellsThe H-loop in the second nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator is required for efficient chloride channel closingComplement yourself: Transcomplementation rescues partially folded mutant proteins.Stable ATP binding mediated by a partial NBD dimer of the CFTR chloride channelMost F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexinADP inhibits function of the ABC transporter cystic fibrosis transmembrane conductance regulator via its adenylate kinase activity.Fast and automated functional classification with MED-SuMo: an application on purine-binding proteins.Decoding F508del misfolding in cystic fibrosis.The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding.Restoration of domain folding and interdomain assembly by second-site suppressors of the DeltaF508 mutation in CFTRDivergent signature motifs of nucleotide binding domains of ABC multidrug transporter, CaCdr1p of pathogenic Candida albicans, are functionally asymmetric and noninterchangeableThe hydroxyl group of S685 in Walker A motif and the carboxyl group of D792 in Walker B motif of NBD1 play a crucial role for multidrug resistance protein folding and function.ATP hydrolysis is required to reset the ATP-binding cassette dimer into the resting-state conformationA single amino acid substitution in CFTR converts ATP to an inhibitory ligand.The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis.
P2860
Q21089686-4776AC7C-C02F-4CCF-B8B5-925078FC7552Q21129277-1B3C2F5C-FE4C-4FC3-A578-5EA6A5EA1A27Q24529132-BD94047E-9CB3-4C88-9ADF-61AF3B9E5A86Q24534836-A6A28436-E6F3-414F-A733-CBC599FA9720Q24657572-8979BB72-C7A4-47E5-AF96-B849161C8A41Q24811329-02014C06-3352-4259-8C07-7BB26AF90527Q26851242-A1D52A62-88E0-4BC7-9026-461C1DCE1679Q27303593-5A0BD61C-6AED-483C-9D1B-D07931A3563FQ27659756-026F317A-D61A-4212-9EDF-D4F28A788183Q27667335-E6289E44-AD28-4323-9461-0A6F6E674F42Q27667829-1DB114AF-9131-46B5-908A-0CA554C824D9Q27676826-C7E8C65D-E71B-49B7-8678-FDCBFD92A64EQ27678196-6AF52ECB-BA38-46E2-9B2D-9CB7548F6BD5Q27934755-81A49F8A-77BB-4BBC-8433-CC8542E8647BQ28073063-98D5F3F3-8185-4BCA-BAF5-DDB930F12C8AQ28472340-4B784A37-B1AB-4EF2-BB3A-CC630C693E6EQ28476393-EEA3F462-656B-4431-8BAD-AF4E3D47DC7CQ28544842-FF343A1E-C55D-4528-B742-E4114FAE7B79Q30395451-FE5BEBAF-E1B2-40CA-B25C-443B80A2F0CBQ30396634-582D7B8F-340A-4035-A11C-06D8CD44B327Q30421217-3DEFAAE8-97B5-443B-9B71-80705DC5F8A0Q30545926-11097822-2C1B-4F5B-AF8D-1FDD63BFF72CQ33325751-0A90E0F6-5131-42B1-9941-AEEEFD82AEF9Q33605591-47A066F6-13AE-458C-B2FB-586D8BAAD83DQ33723395-2979F8A8-8985-4712-9D81-71D9C4DC9EECQ33742138-305E0BF4-0AC4-4E19-A9CF-71CCAFA38EA1Q33750252-BAB7F6FD-2DB3-440F-A0D7-AA333EC5C746Q33763709-CF3BFE65-AC15-41AC-9B13-F743557DAC41Q33814258-FF43A80C-2852-4D10-BDC8-5FD14FDB3260Q33836913-3A91ABC4-662D-4604-AEB8-FB023090428EQ33838222-5C958B0F-6EED-4DB3-9789-0813A21546EDQ33839028-59D4BEDE-3C43-497B-806C-4557CC816E20Q33912624-2CD3004A-4454-413F-AB41-963702321FB0Q33992909-2A6185B1-0D25-41F9-B727-70CAD32819AAQ34017049-B0F6BF7F-D4A3-43AE-95B8-05DEF6DFF53AQ34049370-C27D699D-F1CC-441C-8FF3-F4065F62CF46Q34201794-4A8C9CF5-4BE1-473B-995D-4DBBCDDC022DQ34212621-F3EC4AA6-A208-41E1-92CA-C5B86B2422F3Q34262494-3E91B4D6-AD4A-4A77-9B1A-88FC4EBDB9BEQ34285307-05BD4EEF-6F63-45B7-AE8E-C48380455AA5
P2860
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Structure of nucleotide-bindin ...... membrane conductance regulator
@ast
Structure of nucleotide-bindin ...... membrane conductance regulator
@en
Structure of nucleotide-bindin ...... membrane conductance regulator
@nl
type
label
Structure of nucleotide-bindin ...... membrane conductance regulator
@ast
Structure of nucleotide-bindin ...... membrane conductance regulator
@en
Structure of nucleotide-bindin ...... membrane conductance regulator
@nl
prefLabel
Structure of nucleotide-bindin ...... membrane conductance regulator
@ast
Structure of nucleotide-bindin ...... membrane conductance regulator
@en
Structure of nucleotide-bindin ...... membrane conductance regulator
@nl
P2093
P2860
P3181
P356
P1433
P1476
Structure of nucleotide-bindin ...... membrane conductance regulator
@en
P2093
Don Lorimer
Hal A Lewis
J Michael Sauder
John F Hunt
Kai W Post
Kanagalaghatta R Rajashankar
Kris Conners
Marc E Rutter
Margaret C Kearins
Marie Zhang
P2860
P304
P3181
P356
10.1038/SJ.EMBOJ.7600040
P407
P577
2004-01-28T00:00:00Z